426 related articles for article (PubMed ID: 25896352)
1. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
3. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
Aung MM; Slade K; Freeman LAR; Kos K; Whatmore JL; Shore AC; Gooding KM
Diabetologia; 2019 Sep; 62(9):1701-1711. PubMed ID: 31203378
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).
Htike ZZ; Yates T; Brady EM; Webb D; Gray LJ; Swarbrick D; McCann GP; Khunti K; Davies MJ
Cardiovasc Diabetol; 2016 Jul; 15(1):102. PubMed ID: 27440110
[TBL] [Abstract][Full Text] [Related]
8. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
[TBL] [Abstract][Full Text] [Related]
11. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
12. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
Flint A; Kapitza C; Zdravkovic M
Diabetes Obes Metab; 2013 Oct; 15(10):958-62. PubMed ID: 23551925
[TBL] [Abstract][Full Text] [Related]
13. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
[TBL] [Abstract][Full Text] [Related]
14. The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Nandy D; Johnson C; Basu R; Joyner M; Brett J; Svendsen CB; Basu A
Diab Vasc Dis Res; 2014 Nov; 11(6):419-30. PubMed ID: 25212693
[TBL] [Abstract][Full Text] [Related]
15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
16. Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.
Suhrs HE; Raft KF; Bové K; Madsbad S; Holst JJ; Zander M; Prescott E
Int J Cardiol; 2019 May; 283():28-34. PubMed ID: 30773266
[TBL] [Abstract][Full Text] [Related]
17. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Forst T; Michelson G; Ratter F; Weber MM; Anders S; Mitry M; Wilhelm B; Pfützner A
Diabet Med; 2012 Sep; 29(9):1115-8. PubMed ID: 22288732
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P; Sajadieh A; Anholm C; Kristiansen OP; Haugaard SB; Nielsen OW
Cardiovasc Diabetol; 2021 Jan; 20(1):12. PubMed ID: 33413428
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
